Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer.

Shah JR, Dong T, Phung AT, Khan S, Aisagbonhi O, Blair SL, Bouvet M, Trogler WC, Kummel AC

Open source

DOI
10.1038/s41598-025-00211-2
Published
2025 May 14
Container
Scientific reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-025-00211-2,
  title = {Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer.},
  author = {Shah JR and Dong T and Phung AT and Khan S and Aisagbonhi O and Blair SL and Bouvet M and Trogler WC and Kummel AC},
  year = {2025},
  journal = {Scientific reports},
  doi = {10.1038/s41598-025-00211-2},
  url = {https://doi.org/10.1038/s41598-025-00211-2}
}

RIS

TY  - JOUR
TI  - Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer.
AU  - Shah JR
AU  - Dong T
AU  - Phung AT
AU  - Khan S
AU  - Aisagbonhi O
AU  - Blair SL
AU  - Bouvet M
AU  - Trogler WC
AU  - Kummel AC
PY  - 2025
JO  - Scientific reports
DO  - 10.1038/s41598-025-00211-2
UR  - https://doi.org/10.1038/s41598-025-00211-2
ER  - 

APA

JR, S., T, D., AT, P., S, K., O, A., SL, B., M, B., WC, T., & AC, K. (2025). Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer.. Scientific reports. https://doi.org/10.1038/s41598-025-00211-2

Source records